Company intelligence / Profile preview

Syntone Biopharma

China

Ownership: Private
Development stage: Other

Overview

Syntone Technologies Group serves as a strategic investor/partner for Outlook Therapeutics’ ONS-5010/LYTENAVA™ (bevacizumab gamma), which has achieved centralized marketing authorization in the EU and UK for wet AMD and is investigational (late clinical stage) in the US[5].

Therapeutic areas: Ophthalmology
Modalities: Monoclonal antibody
Industry: Investors

Partnerships

Outlook Therapeutics

Beyond the preview

Go deeper on Syntone Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntone Biopharma.

Explore the full profile